2nd Quarter - Report — REGENXBIO for REGENXBIO (2021)

Firm

REGENXBIO

Client

REGENXBIO

Income

—

Expenses

$40,000

Expense method

A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Immigration IMM

Monitoring for proposed changes in immigration laws affecting non-U.S. citizen scientists and their families.

Lobbyist	Covered position, as disclosed
BRUCE ARTIM	Senate Judiciary Committee Staff Member 1995-2006; (Chief Counsel and Staff Director 2003-04); Intellectual Property Subcommittee - Chief Counsel and Staff Director 2005-06)

Contacted: HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Patent & Trademark Office (PTO); Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); SENATE; State, Dept of (DOS); Justice, Dept of (DOJ); Homeland Security, Dept of (DHS)

Trade (domestic/foreign) TRD

Proposed Covid-19 IP waiver under consideration by the U.S. Congress, Biden Administration and World Trade Administration. Retention of 12 years of regulatory data protection for biologics in international trade agreements.

Lobbyist	Covered position, as disclosed
BRUCE ARTIM	Senate Judiciary Committee Staff Member 1995-2006; (Chief Counsel and Staff Director 2003-04); Intellectual Property Subcommittee - Chief Counsel and Staff Director 2005-06)

Contacted: HOUSE OF REPRESENTATIVES; Justice, Dept of (DOJ); Homeland Security, Dept of (DHS); Food & Drug Administration (FDA); State, Dept of (DOS); Patent & Trademark Office (PTO); SENATE; Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS)

Copyright/Patent/Trademark CPT

Reform of Section 101 of the patent code. IP proposals related to drug pricing legislation including regulatory data protection for biologics, march in rights provisions of the Bayh-Dole Act, and Section 1498 of the patent code.

Lobbyist	Covered position, as disclosed
BRUCE ARTIM	Senate Judiciary Committee Staff Member 1995-2006; (Chief Counsel and Staff Director 2003-04); Intellectual Property Subcommittee - Chief Counsel and Staff Director 2005-06)

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); State, Dept of (DOS); Patent & Trademark Office (PTO); Centers For Medicare and Medicaid Services (CMS); SENATE; Homeland Security, Dept of (DHS); Justice, Dept of (DOJ)

Health Issues HCR

Development of Value Based Agreement (VBA) legislation. Development of this Congress' versions of House and Senate drug pricing legislation (e.g., building upon last Congress' bills, including H.R. 3, H.R. 19, and S. 2543.) Health care provisions of the Covid-19 relief reconciliation bill, H.R. 1319, the American Rescue Plan Act of 2021.

Lobbyist	Covered position, as disclosed
BRUCE ARTIM	Senate Judiciary Committee Staff Member 1995-2006; (Chief Counsel and Staff Director 2003-04); Intellectual Property Subcommittee - Chief Counsel and Staff Director 2005-06)

Contacted: HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Justice, Dept of (DOJ); Health & Human Services, Dept of (HHS); Patent & Trademark Office (PTO); Homeland Security, Dept of (DHS); SENATE; State, Dept of (DOS)

Bills named: H.R. 3 (117th), H.R. 1319 (117th), H.R. 19 (117th), S. 2543 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.